These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 25804339)

  • 21. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
    Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
    Thompson PA; O'Brien SM; Wierda WG; Ferrajoli A; Stingo F; Smith SC; Burger JA; Estrov Z; Jain N; Kantarjian HM; Keating MJ
    Cancer; 2015 Oct; 121(20):3612-21. PubMed ID: 26193999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
    Wierda WG; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJ; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell CA; Osterborg A;
    J Clin Oncol; 2010 Apr; 28(10):1749-55. PubMed ID: 20194866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
    Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia.
    Bergmann L; Fenchel K; Jahn B; Mitrou PS; Hoelzer D
    Ann Oncol; 1993 May; 4(5):371-5. PubMed ID: 8353071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
    Stelitano C; Morabito F; Kropp MG; Callea V; Iuliano F; Oriana V; Levato D; Nobile F; Molica S; Brugiatelli M
    Haematologica; 1999 Apr; 84(4):317-23. PubMed ID: 10190945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia.
    Leporrier M
    Hematol J; 2004; 5 Suppl 1():S10-9. PubMed ID: 15079149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia.
    Cheson BD; Frame JN; Vena D; Quashu N; Sorensen JM
    J Clin Oncol; 1998 Jul; 16(7):2313-20. PubMed ID: 9667245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
    Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
    Bezares RF; Stemelin G; Diaz A; Argentieri D; Zubiaur EL; Garay G; Bartomioli M; Ryser R; Milone G
    Leuk Lymphoma; 2011 Oct; 52(10):1936-41. PubMed ID: 21718136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.
    Langerbeins P; Busch R; Anheier N; Dürig J; Bergmann M; Goebeler ME; Hurtz HJ; Stauch MB; Stilgenbauer S; Döhner H; Fink AM; Cramer P; Fischer K; Wendtner CM; Hallek M; Eichhorst B
    Am J Hematol; 2014 Dec; 89(12):E239-43. PubMed ID: 25196783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.
    Niederle N; Megdenberg D; Balleisen L; Heit W; Knauf W; Weiß J; Freier W; Hinke A; Ibach S; Eimermacher H
    Ann Hematol; 2013 May; 92(5):653-60. PubMed ID: 23340738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
    Giles FJ; O'Brien SM; Santini V; Gandhi V; Plunkett W; Seymour JF; Robertson LE; Kantarjian HM; Keating MJ
    Leuk Lymphoma; 1999 Dec; 36(1-2):57-65. PubMed ID: 10613450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
    Rai KR; Freter CE; Mercier RJ; Cooper MR; Mitchell BS; Stadtmauer EA; Santábarbara P; Wacker B; Brettman L
    J Clin Oncol; 2002 Sep; 20(18):3891-7. PubMed ID: 12228210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients.
    Cortelezzi A; Gritti G; Laurenti L; Cuneo A; Ciolli S; Di Renzo N; Musto P; Mauro FR; Cascavilla N; Falchi L; Zallio F; Callea V; Maura F; Martinelli S; Piciocchi A; Reda G; Foà R;
    Br J Haematol; 2012 Feb; 156(4):481-9. PubMed ID: 22150204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
    Hoyle M; Crathorne L; Garside R; Hyde C
    Health Technol Assess; 2011 May; 15 Suppl 1():61-7. PubMed ID: 21609654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia.
    Xu W; Miao KR; Zhu DX; Fang C; Zhu HY; Dong HJ; Wang DM; Wu YJ; Qiao C; Li JY
    Int J Cancer; 2011 May; 128(9):2192-201. PubMed ID: 20635386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia.
    Hocepied AM; Falkson CI; Falkson G
    S Afr Med J; 1996 May; 86(5):549-50. PubMed ID: 8711555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.